What C4X does
To achieve this goal it is using cutting-edge technologies and expertise to efficiently deliver small-molecule (pharmaceutical) medicines.
It has a unique software platform for determining the flexible 3D shapes of drug molecules from experimental data.
This enables the rapid design and discovery of novel and potent drugs for diseases with high unmet medical need across broad therapeutic areas.
Unlike many drug companies, it looks to find partners at the pre-clinical phase, allowing big pharma to fund expensive human trials.
It successfully out-licensed its programme for addictive disorders to Indivior, receiving an upfront £7.7mln (US$10mln) and milestones of £227mln (US$294mln).
It is working on potential treatments for Parkinson’s, Alzheimer’s and inflammatory bowel disorders and it has numerous collaboration deals.
Below is the company’s drug pipeline
The company is well-funded, having just completed a £6.6mln fundraise, with 46,466,667 shares placed by Panmure Gordon today at a price of 15p each.
On 24 October, C4X unveiled plans to raise around £6.5mln to strengthen its balance sheet amid ongoing licensing discussions for its early-stage drug candidates.
In a recent business update, C4X said it was “very confident” of delivering deals in the near future. It said it is in licensing discussions with potential partners for two of its early-stage drugs, while collaborations with two life sciences groups are making progress.
Chief executive Clive Dix said its NRF-2 activator had the potential to become an alternative treatment for people poorly served by the current sickle cell medication. This is supported by recent industry data on the condition.
In the update, C4X also noted there had been “strong interest from potential partners” for its oral IL-17 inhibitor for inflammation.
Its partnership with LifeArc, announced just under a year ago, is also proving a success, while another tie-up, this time with AIM-listed Horizon Developments (LON:HZD), inked last December, has made “rapid progress”.
Also on the horizon is the first clinical trial of its molecule to treat opioid addiction, which was licensed to Indivior last year. In December, Altasciences was selected to conduct a phase I study in two parts, to test the safety and tolerability of the treatment, as well as how it behaves in the body.
Watch the interview
What the boss says:
Chief executive, Clive Dix, explaine the recent fundraise: “We’re building a portfolio that’s highly valuable and we need to keep adding to that portfolio with time. We need to get it to a state where the molecules can come off the strack and we license them. That takes time and cash."
We have eleven programmes, of which three three are relatively near term for licensing. But they do need to carry on progressing and maturing."
On the current valuation of the business, Dix says: ''It's a bargain for anyone who knows and understands the healthcare sector well''.